Proceedings Of The 23Rd Paediatric Rheumatology European Society Congress: Part Two

Dermatologic adverse events associated with Juvenile Idiopathic Arthritis treatment

Introduction: Steroids and disease-modifying anti-rheumatic drugs (DMARDs) are widely used in the treatment of juvenile idiopathic arthritis (JIA). Dermatologic adverse events including psoriasis have been reported in treatment of various inflammatory diseases (1-3). However, data regarding the occurrence of dermatologic adverse events in JIA patients are scarce (4-6). Objectives: To determine the prevalence of dermatologic adverse events in JIA patients treated with systemic steroids and DMARDs. To investigate an association between drugs and dermatologic adverse events and the association between anti-TNF treatment and psoriasiform lesions.

TASSO DI PERSISTENZA IN TERAPIA E FATTORI PREDITTIVI DI SOPRAVVIVENZA DEGLI INIBITORI DELL’INTERLEUCHINA 1 NELL’ARTRITE IDIOPATICA GIOVANILE A ESORDIO SISTEMICO

INTRODUZIONE L’introduzione dei farmaci biologici ha rivoluzionato l’approccio terapeutico nell’Artrite Idiopatica Giovanile a esordio Sistemico (SoJIA), modificando la storia naturale di questa malattia e migliorandone l’outcome globale. METODI Obiettivo principale dello studio era analizzare il tasso di persistenza in terapia (DRR) degli inibitori dell’Interleuchina (IL)-1 nei pazienti affetti da SoJIA. Obiettivi secondari dello studio erano: (1) esplorare l’influenza della linea biologica di trattamento, degli eventi avversi, dello specifico agente anti-IL-1 e del cotrattamento con disease modifying anti-rheumatic drugs (cDMARDs) sul DRR; (2) identificare eventuali fattori predittivi ass…

Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part one

Disease activity states, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept

The advent of biologic medications has increased considerably the potential for treatment benefit in juvenile idiopathic arthritis (JIA), with clinical remission being now achievable in a substantial proportion of patients. However, there is a need of data from the real world of clinical practice to evaluate thoroughly the efficacy and safety profile of the biologic agents currently approved.

Adherence to colchicine treatment and colchicine resistance in a multicentric FMF national cohort

Introduction: Colchicine is the standard treatment for Familiar Mediterranean Fever (FMF), however about 5% of patients (pts) experience colchicine resistance. There is no standard definition of colchicine resistance. Recently a panel of experts elaborated a new definition based on a Delphi consensus approach. Objectives: We aim to describe main features of the disease and clinical outcome of a cohort of FMF pts with particular interest on the colchicine resistance and tolerability according to the definitions proposed by the recent consensus.

EVALUATION OF THE DISEASE COURSE OF ITALIAN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS TREATED WITH ETANERCEPT: PRELIMINARY RESULTS IN 1019 PATIENTS

Methods: This is a multicenter, observational study that includes all children with JIA who were given ETN at Italian pediatric rheumatology centers after January 2000. Patients were classified in 2 groups: patients who were no longer taking ETN at study start (Group 1); patients who were still receiving ETN at study start (Group 2). Patients in Group 1 underwent only retrospective assessments, whereas patients in Group 2 underwent both retrospective and cross-sectional assessments. The primary outcome of the study were reasons for ETN discontinuation in patients in Group 1, and achievement of the states of inactive disease (ID), minimal disease activity (MDA) and parent- and child-acceptab…